A California federal court on Thursday handed a partial win to Allergan USA Inc. by blocking the compound drugmaker Imprimis Pharmaceuticals from selling medications under certain conditions, though the judge limited the order’s scope to the Golden State…

Read this piece in its entirety at Law360.